Eaton Vance Tax Advantaged Dividend (EVT) 20.89 $EVT
Distribution Dates and Amounts Announced for Certain Eaton Vance Closed-End Funds
PR Newswire - Tue Feb 10, 1:37PM CST
Eaton Vance closed-end funds (the "Funds"
announced distributions today as detailed below.
EXG: 9.67 (+0.04), ETG: 16.61 (+0.10), EVG: 14.36 (+0.02), ETJ: 10.88 (+0.01), EFT: 14.21 (+0.02), EFR: 14.01 (+0.06), EV: 42.58 (+0.29), ETB: 16.08 (+0.11), EOS: 14.19 (+0.11), ETO: 24.35 (+0.27), EVT: 20.89 (+0.03), ETV: 14.67 (-0.01), ETY: 11.52 (+0.05), ETW: 11.79 (-0.06), EOI: 14.05 (+0.09), EFF: 16.60 (+0.01)
Equity CEFs: Global CEFs For A QE Europe
Douglas Albo - at Seeking Alpha - Mon Jan 26, 12:07PM CST
IID: 8.02 (+0.08), ETO: 24.35 (+0.27), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), IEV: 44.50 (+0.15), ETG: 16.61 (+0.10), EVT: 20.89 (+0.03), AGD: 10.23 (+0.13), DIA: 180.34 (+0.50), EFA: 63.82 (+0.42), AOD: 8.75 (+0.05)
Evotec Achieves Further Milestones in TargetAD Collaboration With Janssen
GlobeNewswire - Thu Jan 15, 12:35AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen" for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process. These milestones were reached in 2014 which will be recognised in the financial year 2014.
EVT: 20.89 (+0.03)
Evotec and Padlock Therapeutics Announce Initial Success and Extension of Long-Term Collaboration
GlobeNewswire - Wed Jan 07, 12:37AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN E0005664809) and Padlock Therapeutics, Inc. ("Padlock" announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014. Padlock is a company that is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation and immune complex formation in autoimmune diseases.
EVT: 20.89 (+0.03)
Equity CEFs: Will 2015 Be The Year Of The Rotation?
Douglas Albo - at Seeking Alpha - Mon Dec 29, 10:18AM CST
GNT: 8.54 (+0.13), SPY: 209.78 (+0.86), EVT: 20.89 (+0.03), SCD: 16.98 (-0.05), GLD: 117.98 (+0.64), GRX: 10.81 (-0.04), UTF: 23.01 (+0.07), QQQX: 19.12 (+0.08), GGN: 7.59 (+0.12)
Eaton Vance Declares Early Monthly Distributions and Capital Gain Distributions for Certain Eaton Vance Closed-End Funds
PR Newswire - Fri Dec 19, 3:36PM CST
Eaton Vance closed-end funds (the "Funds" announced distributions today as detailed below.
ETO: 24.35 (+0.27), EVT: 20.89 (+0.03), EFT: 14.21 (+0.02), EFR: 14.01 (+0.06), EV: 42.58 (+0.29), EFF: 16.60 (+0.01)
Monday's Ex-Dividends To Watch: EVG, EFT, EVT
at The Street - Fri Dec 19, 9:06AM CST
EVG EFT EVT are going ex-dividend Monday, Monday, December 22, 2014
EVT: 20.89 (+0.03), EVG: 14.36 (+0.02), EFT: 14.21 (+0.02)
Achievement of Multiple Milestones in Evotec's Drug Discovery Alliances
GlobeNewswire - Thu Dec 18, 11:57AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN E0005664809) disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners. The milestones were reached in its multi-target collaboration with Bayer HealthCare ("Bayer" in endometriosis and within its partnership with Janssen Pharmaceuticals, Inc. ("Janssen" for the EVT100 series for the treatment of CNS diseases. These milestones trigger revenues of approx. EUR 8 m in total which will be recognised in the financial year 2014.
EVT: 20.89 (+0.03)
Eaton Vance Tax-Advantaged Dividend Income Fund declares $0.1158 distribution
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:14AM CST
EVT: 20.89 (+0.03)
Eaton Vance Tax-Advantaged Dividend Income Fund Report Of Earnings
PR Newswire - Mon Nov 24, 3:01PM CST
Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT), a diversified closed-end management investment company, today announced the earnings of the Fund for the three months and year ended August 31, 2014. The Fund's fiscal year ended on August 31, 2014.
EVT: 20.89 (+0.03), EV: 42.58 (+0.29)
Evotec to Report Results for the First Nine Months of 2014 on 12 November 2014
GlobeNewswire - Wed Nov 05, 5:59AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN E0005664809) will report its financial results for the first nine months of 2014 on Wednesday, 12 November 2014.
EVT: 20.89 (+0.03)
Equity CEFs: Funds To Buy And Sell Heading Into 2015
Douglas Albo - at Seeking Alpha - Mon Oct 27, 4:56PM CDT
ETG: 16.61 (+0.10), KYE: 26.13 (-0.18), AWP: 6.81 (-0.02), HQL: 27.40 (+0.16), SCD: 16.98 (-0.05), CEM: 26.42 (+0.18), ETO: 24.35 (+0.27), PGP: 21.63 (+0.17), SPY: 209.78 (+0.86), EVT: 20.89 (+0.03), RFI: 13.35 (-0.02), GRX: 10.81 (-0.04), NTG: 26.13 (+0.13), UTF: 23.01 (+0.07), HQH: 34.20 (+0.06), RQI: 12.36 (-0.10)
Evotec Receives Milestone as Part of Its Multi-Target Alliance With Bayer HealthCare
GlobeNewswire - Tue Sep 30, 12:39AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN E0005664809) announced today that its multi-target collaboration with Bayer HealthCare ("Bayer" has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis.
EVT: 20.89 (+0.03)
Eaton Vance Management Announces Portfolio Managers Of Eaton Vance Tax-Advantaged Dividend Income Fund And Eaton Vance Enhanced Equity Income Fund II
PR Newswire - Mon Sep 29, 3:01PM CDT
Eaton Vance Management ("EVM" , a subsidiary of Eaton Vance Corp. ("Eaton Vance" , announced that effective September 30, 2014, Edward Perkin and John Crowley will join the portfolio management team of Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT) and Lew Piantedosi and Yana Barton will join the portfolio management team of Eaton Vance Enhanced Equity Income Fund II (NYSE: EOS). Mr. Perkin is Vice President and Chief Equity Investment Officer of EVM. Messrs. Crowley and Piantedosi and Ms. Barton are Vice Presidents of EVM. Each co-manages other portfolios advised by EVM.
EVT: 20.89 (+0.03), EV: 42.58 (+0.29), EOS: 14.19 (+0.11)
Evotec and Its Partners Awarded Public Grants to Develop New Drug Candidates to Treat Multiple Sclerosis
GlobeNewswire - Wed Sep 24, 12:35AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN E0005664809) announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis ("MS" supported by research funds from the German Federal Ministry of Education and Research ("BMBF" .
EVT: 20.89 (+0.03)
Evotec Takes Legal Steps Against Andromeda Biotech, Ltd.
GlobeNewswire - Thu Sep 18, 12:35AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN E0005664809) announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. ("Andromeda" to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277.
EVT: 20.89 (+0.03), HPTX: 26.83 (-0.05)
Distribution Dates and Amounts Announced for Certain Eaton Vance Closed-End Funds
PR Newswire - Tue Feb 10, 1:37PM CST
Eaton Vance closed-end funds (the "Funds"
announced distributions today as detailed below. EXG: 9.67 (+0.04), ETG: 16.61 (+0.10), EVG: 14.36 (+0.02), ETJ: 10.88 (+0.01), EFT: 14.21 (+0.02), EFR: 14.01 (+0.06), EV: 42.58 (+0.29), ETB: 16.08 (+0.11), EOS: 14.19 (+0.11), ETO: 24.35 (+0.27), EVT: 20.89 (+0.03), ETV: 14.67 (-0.01), ETY: 11.52 (+0.05), ETW: 11.79 (-0.06), EOI: 14.05 (+0.09), EFF: 16.60 (+0.01)
Equity CEFs: Global CEFs For A QE Europe
Douglas Albo - at Seeking Alpha - Mon Jan 26, 12:07PM CST
IID: 8.02 (+0.08), ETO: 24.35 (+0.27), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), IEV: 44.50 (+0.15), ETG: 16.61 (+0.10), EVT: 20.89 (+0.03), AGD: 10.23 (+0.13), DIA: 180.34 (+0.50), EFA: 63.82 (+0.42), AOD: 8.75 (+0.05)
Evotec Achieves Further Milestones in TargetAD Collaboration With Janssen
GlobeNewswire - Thu Jan 15, 12:35AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen" for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process. These milestones were reached in 2014 which will be recognised in the financial year 2014. EVT: 20.89 (+0.03)
Evotec and Padlock Therapeutics Announce Initial Success and Extension of Long-Term Collaboration
GlobeNewswire - Wed Jan 07, 12:37AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) and Padlock Therapeutics, Inc. ("Padlock" announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014. Padlock is a company that is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation and immune complex formation in autoimmune diseases. EVT: 20.89 (+0.03)
Equity CEFs: Will 2015 Be The Year Of The Rotation?
Douglas Albo - at Seeking Alpha - Mon Dec 29, 10:18AM CST
GNT: 8.54 (+0.13), SPY: 209.78 (+0.86), EVT: 20.89 (+0.03), SCD: 16.98 (-0.05), GLD: 117.98 (+0.64), GRX: 10.81 (-0.04), UTF: 23.01 (+0.07), QQQX: 19.12 (+0.08), GGN: 7.59 (+0.12)
Eaton Vance Declares Early Monthly Distributions and Capital Gain Distributions for Certain Eaton Vance Closed-End Funds
PR Newswire - Fri Dec 19, 3:36PM CST
Eaton Vance closed-end funds (the "Funds"
announced distributions today as detailed below. ETO: 24.35 (+0.27), EVT: 20.89 (+0.03), EFT: 14.21 (+0.02), EFR: 14.01 (+0.06), EV: 42.58 (+0.29), EFF: 16.60 (+0.01)
Monday's Ex-Dividends To Watch: EVG, EFT, EVT
at The Street - Fri Dec 19, 9:06AM CST
EVG EFT EVT are going ex-dividend Monday, Monday, December 22, 2014
EVT: 20.89 (+0.03), EVG: 14.36 (+0.02), EFT: 14.21 (+0.02)
Achievement of Multiple Milestones in Evotec's Drug Discovery Alliances
GlobeNewswire - Thu Dec 18, 11:57AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners. The milestones were reached in its multi-target collaboration with Bayer HealthCare ("Bayer" in endometriosis and within its partnership with Janssen Pharmaceuticals, Inc. ("Janssen" for the EVT100 series for the treatment of CNS diseases. These milestones trigger revenues of approx. EUR 8 m in total which will be recognised in the financial year 2014. EVT: 20.89 (+0.03)
Eaton Vance Tax-Advantaged Dividend Income Fund declares $0.1158 distribution
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:14AM CST
EVT: 20.89 (+0.03)
Eaton Vance Tax-Advantaged Dividend Income Fund Report Of Earnings
PR Newswire - Mon Nov 24, 3:01PM CST
Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT), a diversified closed-end management investment company, today announced the earnings of the Fund for the three months and year ended August 31, 2014. The Fund's fiscal year ended on August 31, 2014.
EVT: 20.89 (+0.03), EV: 42.58 (+0.29)
Evotec to Report Results for the First Nine Months of 2014 on 12 November 2014
GlobeNewswire - Wed Nov 05, 5:59AM CST
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) will report its financial results for the first nine months of 2014 on Wednesday, 12 November 2014. EVT: 20.89 (+0.03)
Equity CEFs: Funds To Buy And Sell Heading Into 2015
Douglas Albo - at Seeking Alpha - Mon Oct 27, 4:56PM CDT
ETG: 16.61 (+0.10), KYE: 26.13 (-0.18), AWP: 6.81 (-0.02), HQL: 27.40 (+0.16), SCD: 16.98 (-0.05), CEM: 26.42 (+0.18), ETO: 24.35 (+0.27), PGP: 21.63 (+0.17), SPY: 209.78 (+0.86), EVT: 20.89 (+0.03), RFI: 13.35 (-0.02), GRX: 10.81 (-0.04), NTG: 26.13 (+0.13), UTF: 23.01 (+0.07), HQH: 34.20 (+0.06), RQI: 12.36 (-0.10)
Evotec Receives Milestone as Part of Its Multi-Target Alliance With Bayer HealthCare
GlobeNewswire - Tue Sep 30, 12:39AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) announced today that its multi-target collaboration with Bayer HealthCare ("Bayer" has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis. EVT: 20.89 (+0.03)
Eaton Vance Management Announces Portfolio Managers Of Eaton Vance Tax-Advantaged Dividend Income Fund And Eaton Vance Enhanced Equity Income Fund II
PR Newswire - Mon Sep 29, 3:01PM CDT
Eaton Vance Management ("EVM"
, a subsidiary of Eaton Vance Corp. ("Eaton Vance" , announced that effective September 30, 2014, Edward Perkin and John Crowley will join the portfolio management team of Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT) and Lew Piantedosi and Yana Barton will join the portfolio management team of Eaton Vance Enhanced Equity Income Fund II (NYSE: EOS). Mr. Perkin is Vice President and Chief Equity Investment Officer of EVM. Messrs. Crowley and Piantedosi and Ms. Barton are Vice Presidents of EVM. Each co-manages other portfolios advised by EVM. EVT: 20.89 (+0.03), EV: 42.58 (+0.29), EOS: 14.19 (+0.11)
Evotec and Its Partners Awarded Public Grants to Develop New Drug Candidates to Treat Multiple Sclerosis
GlobeNewswire - Wed Sep 24, 12:35AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis ("MS" supported by research funds from the German Federal Ministry of Education and Research ("BMBF" . EVT: 20.89 (+0.03)
Evotec Takes Legal Steps Against Andromeda Biotech, Ltd.
GlobeNewswire - Thu Sep 18, 12:35AM CDT
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN
E0005664809) announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. ("Andromeda" to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277. EVT: 20.89 (+0.03), HPTX: 26.83 (-0.05)
